

Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study

Davide Giusti,¹ Elisabetta Colaci,¹ Valeria Pioli,¹ Federico Banchelli,² Monica Maccaferri,¹ Giovanna Leonardi,¹ Roberto Marasca,¹ Monica Morselli,¹ Fabio Forghieri,¹ Francesca Bettelli,¹ Angela Cuoghi,¹ Paola Bresciani,¹ Andrea Messerotti,¹ Andrea Gilioli,¹ Anna Candoni,¹ Luca Cassanelli,¹ Elena Sbadili,¹ Ilaria Bassoli,³ Giuseppe Longo,⁴ Fabio Gilioli,⁵ Eleonora Borelli ⁽¹⁾, ¹ Sarah Bigi,⁶ Roberto D'Amico,² Carlo Adolfo Porro,^{7,8} Oreofe Odejide,⁹ Camilla Zimmermann ⁽¹⁾, ^{10,11} Fabio Efficace ⁽¹⁾, ¹² Eduardo Bruera ⁽¹⁾, ¹³ Mario Luppi ⁽¹⁾, ¹ Elena Bandieri,¹⁴ Leonardo Potenza ⁽¹⁾

ABSTRACT

Objectives Although early palliative care (EPC) is beneficial in acute myeloid leukaemia, little is known about EPC value in multiple myeloma (MM). We compared quality indicators for palliative and end-of-life (EOL) care in patients with MM receiving EPC with those of patients who received usual haematological care (UHC).

Methods This observational, retrospective study was based on 290 consecutive patients with MM. The following indicators were abstracted: providing psychological support, assessing/managing pain, discussing goals of care, promoting advance care plan, accessing home care services; no anti-MM treatment within 14 and 30 days and hospice length of stay >7 days before death; no cardiopulmonary resuscitation, no intubation, <2 hospitalisations and emergency department visits within 30 days before death. Comparisons were performed using unadjusted and confounderadjusted regression models.

Results 55 patients received EPC and 231 UHC. Compared with UHC patients, EPC patients had a significantly higher number of quality indicators of care (mean 2.62 ± 1.25 vs 1.12 ± 0.95 ; p<0.0001)); a significant reduction of pain intensity over time (p<0.01) and a trend towards reduced aggressiveness at EOL, with the same survival (5.3 vs 5.46 years; p=0.74)).

Conclusions Our data support the value of integrating EPC into MM routine practice and lay the groundwork for future prospective comparative studies.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Early palliative care (EPC) is beneficial for patients with acute myeloid leukaemia or undergoing stem cell transplant but there are scanty information about its effect in patients with other haematological malignancies (HM).

WHAT THIS STUDY ADDS

⇒ Patients with multiple myeloma (MM) receiving EPC, when compared with those undergoing usual haematological care, have better pain control, with longer use of strong opioids; higher rates of symptom management; more frequent goals of care discussions; earlier access to home care services and a trend towards higher quality of end-of-life care.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study supports the value of integrating EPC into MM routine practice and may also lay the groundwork for future prospective comparative studies either in this setting or in patients with other HM.

INTRODUCTION

Early palliative care (EPC) in patients with advanced solid cancers has shown several benefits, including increased survival.¹

Recent studies have demonstrated that provision of EPC is useful also for patients undergoing stem cell transplantation and with acute myeloid leukaemia and recommended it as the new standard of care in this latter setting.^{2–5} This success has raised

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/spcare-2023-004524).

For numbered affiliations see end of article.

Correspondence to

Professor Leonardo Potenza, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; leonardo.potenza@unimore.it

OO, CZ, FE, EBr, ML, EBa and LP contributed equally.

Received 27 July 2023 Accepted 1 August 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Giusti D, Colaci E, Pioli V, et al. BMJ Supportive & Palliative Care Epub ahead of print: [please include Day Month Year]. doi:10.1136/ spcare-2023-004524

Short report

the need to identify other patients with haematological malignancies (HM) who may benefit from EPC.⁶ Patients with multiple myeloma (MM) represent a prime example of a population that could potentially benefit from this approach, as MM is incurable and affected patients typically experience high and unmet symptom needs.⁷⁸

On these grounds, we examined the presence of quality indicators for palliative and end-of-life (EOL) care in a cohort of consecutive patients with MM receiving outpatient EPC and compared them with those of a cohort of patients receiving usual haematological care (UHC).

PATIENTS AND METHODS

Study design and outcome

This is a retrospective cohort study of patients with MM who received EPC or UHC. We compared primary outcomes of quality indicators of PC and EOL care in patients who received EPC versus UHC. We also secondarily compared the number of treatments and overall survival (OS) between the EPC and UHC groups.

Population and interventions

From January 2011 to December 2020, all consecutive MM patients who had their treatment initiated at the study institution were considered eligible for this study. The demographic and clinical data extracted from hospital chart were reported in online supplemental material.

EPC was defined as integration of palliative care within 8 weeks from cancer diagnosis, as previously reported.¹⁴ After starting in that time frame from the diagnosis of MM, the EPC visits were delivered as previously described⁴ and reported in details in online supplemental material.

Usual haematological care

The frequency of UHC visits depended on the patient's specific MM treatment plan. Patients undergoing UHC received standard haematological care with the supportive care measures instituted by the haematological team. The haematologists who provided UHC had not any training in palliative care.

Quality indicators for palliative and EOL care

We conducted electronically structured and comprehensive reviews of electronic hospital chart to determine the presence of quality indicators for palliative and EOL care for EPC and for UHC patients as previously reported⁴ and described in details in online supplemental material.

Statistical analysis

The statistical analysis is described in details in online supplemental material.

We used the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) cohort checklist when writing our report.⁹

RESULTS

Overall 290 consecutive patients with MM were enrolled. Four were excluded because they had started treatment at other institutions before transitioning their care to the study institution. Of the remaining 286 patients, 55 received EPC and 231 received UHC (online supplemental figure S1). Median time of follow-up was 41 (range 1–117) months for EPC and 38 (range 1–118) for UHC patients. Clinical characteristics of the patients are detailed in online supplemental table S1.

Quality indicators of palliative care

Table 1 shows that EPC patients received a significantly higher number of quality indicators of PC compared with UHC patients, (mean 2.62 ± 1.25 vs 1.12 ± 0.95 (adjusted MR 2.18 (95% CI 1.75 to 2.73; p<0.001)) (online supplemental figure S1A,B).

In the EPC group, the median times from the first documented goals of care (GOC) discussion and ACP promotion to death were 162 days (range 3–1368) and 76 days (range 3–924), compared with 29 days (range 2–1595) for GOC in UHC patients, (p<0.001 and no calculable). The difference between patients of the two cohorts accessing home care services was not statistically significant (table 1).

In EPC patients but not in UHC patients, reduction in pain intensity improved significantly over time across the time points considered [mean Numeric Rating Scale (NRS) values 1.86 ± 2.78 at T0, 1.03 ± 2.24 at week 1 (p=0.01); 0.41 ± 1.57 at week 4 (p=0.001)] (online supplemental table S2A).

Consistent with this, 40 (72.7%) out of 55 EPC patients received treatment with strong opioids

Table 1 Quality indicators for palliative care in patients with multiple myeloma receiving EPC or UHC					
Indicators	EPC N=55 (%)	UHC N=231 (%)	Measure	Adjusted (95%CI)	P value
Psychological Support	64.4	28.6	OR	4.64 (2.41 to 8.43)	<0.0001
Assessing and managing pain	100	68.4	OR	nc	nc
Discussion of GOC	74.6	4.3	HR	21.44 (9.75 to 47.16)	<0.0001
Promotion of ACP	13.6	0.0	HR	nc	nc
Home care service utilisation	30.5	22.5	HR	1.1 (0.84 to 2.71)	0.1638

The analysis was adjusted for the following variables in the regression models: age (years), sex (male, female), stage (I, II, III), MMFS = Multiple Myeloma Frailty Score (fit, unfit, frail), intensity of first-line therapy (transplant, no transplant).

ACP, advanced care planning; EPC, early palliative care patients; GOC, goals of care; n, number; nc, no calculable; UHC, usual haematological care.

compared with 129 (55.8%) UHC patients (adjusted OR 1.88 (95% CI 0.93 to 3.82; p=0.07)).

Mean duration of treatment with strong opioids was significantly longer in EPC than in UHC patients (p < 0.001)) (online supplemental table S2B).

Quality indicators of EOL care

Of the entire study cohort, 115 patients died (22 in the EPC group, 93 in the UHC group) and formed the group in which we assessed quality of EOL care.

The analysis of the indicators of aggressiveness at EOL showed that, compared with UHC patients, EPC patients were less likely to receive aggressiveness at the EOL. However, these differences were not statistically significant (online supplemental table S3).

Number of treatment lines and OS

We calculated the number of treatment lines received by patients of the two cohort and whether differences in such a number could have influenced the survival. Compared with UHC patients, the EPC group received a lower mean number of treatment lines $(1.53\pm0.77$ vs 1.90 ± 1.21 , MR of 0.76 (95% CI 0.60 to 0.97; p=0.03)) and less frequently three and four or more lines of treatment (adjusted OR 0.33 (95% CI 0.13 to 0.86; p=0.02) and 0.11 (95% CI 0.01 to 0.89; p=0.03, respectively) (online supplemental table S1 and figure S3A).

Median OS was 5.30 years for EPC group and 5.46 years for UHC group (adjusted HR 0.92; 95% CI 0.56 to 1.51; p=0.7429) (online supplemental figure S3B).

DISCUSSION

In this retrospective cohort study comparing patients with MM receiving EPC versus usual care, those receiving EPC had better pain control, with longer use of strong opioids; higher rates of symptom management; more frequent GOC discussions, earlier in the disease trajectory and a trend towards higher quality of EOL care.

Pain is the most frequent symptom and the most common cause of first PC consultation in patients with MM.^{7 10} A recent study reported that a PC intervention within 1 year from diagnosis may significantly contribute to its reduction.¹¹ Our study provides novel insights by showing that in EPC patients, pain intensity was reduced already after 1 week, and throughout the follow-up, which was not the case for patients having received UHC. This finding underscores the relevance of integrating PC as early as possible in the disease trajectory of patients with MM.

Further primary clinical concerns of MM patients are represented by decreased emotional, physical and social functioning, coping with side effects and information needs.⁷ ¹² In our study, EPC patients were offered more frequently psychological support and obtained more information about the likely trajectory of the disease than UHC patients. These results, which

are in line with previous observations in other cancer populations, indicate that EPC may provide a better coverage of MM patients' needs and support its implementation also in MM routine practice settings.^{2–4}

Guidelines in solid tumours and recent reviews in HM recommend engaging patients in conversations weighing explicitly the benefits and risks of continuing with disease-directed therapies and evaluating symptom-directed care.⁶ ¹³ Our findings indicate that EPC patients were more frequently involved in discussions of prognosis and GOC and in the promotion of ACP than UHC patients.

Our study did not show a significant decrease of aggressiveness of care at the EOL, although EPC patients showed reduced ratios in 7 out of 7 indicators. However, it should be noted that less than 5% of EPC MM patients received anti-MM treatment in the last 14 days of life, when receipt of disease-directed therapies by less than 10% of patients with cancer in that timespan has been described as a condition associated with less aggressiveness of care.¹⁴ Moreover, the percentage of our EPC patients receiving anti-MM treatment in the last month of life is less than the 34% reported in a previous study of MM patients undergoing late palliative care, and suggests, again, that an earlier PC intervention may be associated with further reduction of aggressiveness at EOL.¹⁴

The trend for a reduced aggressiveness at EOL is further supported by the observation that significantly fewer EPC than UHC patients received three or more lines of treatment. Of note, prioritising symptomdirected care instead of disease-directed therapies did not negatively affect survival, as the OS of our EPC patients was similar to those of patients receiving UHC and similar to that reported in the literature.⁸

Our study has several limitations. The first one is the retrospective nature of the data. Also, incomplete data reporting may have underestimated the quality-of-care measures. Finally, being a single-centre study, results may have limited generalisability to other centres where trained supportive and palliative care teams may not be available. These limitations notwithstanding, our study represents one of the most comprehensive reports on patients with MM treated in a real-world setting and having received EPC.

In conclusion, our results suggest that EPC is feasible in patients with MM and results in better quality of care, including better management of pain, more psychological support, more frequent GOC and ACP discussions and a trend to reduced aggressiveness at the EOL, without negatively impacting survival. Our findings may also lay the groundwork for future prospective comparative studies in patients with MM.

Author affiliations

3

¹Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy

²Statistic Unit, Department of Medical and Surgical Sciences, UNIMORE, Modena, Italy

³Pediatrics Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy

⁴Oncological Medicine Unit, Azienda Ospedaliera Universitaria di Modena, Modena, Italy

⁵Department of Internal Medicine and Rehabilitation, Local Health Agency, Carpi, Italy

⁶Department of Linguistic Sciences and Foreign Literatures, Catholic University of the Sacred Heart, Milano, Italy

⁷Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

⁸Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy

⁹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

¹⁰Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

¹¹Department of Medicine, University of Toronto, Toronto, Ontario, Canada

¹²Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy

¹³Palliative Care & Rehabilitation Medicine, UT M. D. Anderson Cancer Center, Houston, Texas, USA

¹⁴Oncology and Palliative Care Units, Civil Hospital Carpi, Local Health Agency (USL), Modena, Italy

Contributors DG and LP have full access to all of the data used in the study and take the responsibility for the integrity of the data and the accuracy of the data analysis. DG, EC, VP, FBa, MMa, GL, MMo, FF, RM, FBe, AC, PB, AM, AG, IB, RD'A and LP have contributed to the acquisition, analysis and interpretation of data. LC, ES, GL, FG, EBo, SB, CAP, FE, OO, CZ, EBr, ML and EBa have commented on manuscript draft, final version and approved the submitted manuscript. FBa and RD'A performed statistical analysis.

Funding This research was partly supported by the Fondazione GIMEMA Franco Mandelli onlus and PNRR CN3 Terapia Genica-Spoke 2 (ML).

Competing interests FF: advisory boards for Jannsen and Novartis and travel grants from Jazz Pharmaceuticals outside the submitted work. RM: honoraria from AbbVie, Roche, Janssen, and Shire, outside the submitted work. FE: consultancy for Abbvie, Amgen, Janssen, Orsenix, Takeda, and grants from Amgen (to his Institution), outside the submitted work. EB: grants from Helsinn Healthcare, outside of the submitted work. ML: advisory board Abbvie, Novartis, Gilead science, Jazz Pharmaceuticals, Sanofi, MSD, Daiichi-Sankyo, Travel grant Gilead science.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by local Ethics Committee, protocol no. CE 833/2018. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; internally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non

Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is noncommercial. See: http://creativecommons.org/licenses/by-nc/4. 0/.

ORCID iDs

Eleonora Borelli http://orcid.org/0000-0002-3391-4437 Camilla Zimmermann http://orcid.org/0000-0003-4889-0244 Fabio Efficace http://orcid.org/0000-0002-5065-5166 Eduardo Bruera http://orcid.org/0000-0002-8745-0412 Mario Luppi http://orcid.org/0000-0002-0373-1154 Leonardo Potenza http://orcid.org/0000-0002-2738-6105

REFERENCES

- 1 Ferrell BR, Temel JS, Temin S, *et al.* Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2017;35:96–112.
- 2 El-Jawahri A, LeBlanc T, VanDusen H, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA 2016;316:2094–103.
- 3 El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial. JAMA Oncol 2021;7:238–45.
- 4 Potenza L, Scaravaglio M, Fortuna D, et al. Early palliative/ supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study. BMJ Support Palliat Care 2021. 10.1136/ bmjspcare-2021-002898 [Epub ahead of print 8 Nov 2021].
- 5 Rodin G, Malfitano C, Rydall A, et al. Emotion and symptomfocused engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia. Support Care Cancer 2020;28:163–76.
- 6 Odejide OO. Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas. *Hematology Am Soc Hematol Educ Program* 2020;2020:148– 53.
- 7 Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol 2019;37:1228–63.
- 8 Elm E von, Altman DG, Egger M, *et al.* Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;335:806–8.
- 9 Pallotti MC, Rossi R, Scarpi E, *et al.* Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes. *Support Care Cancer* 2022;30:2293–8.
- 10 Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, *et al.* Is early palliative care feasible in patients with multiple myeloma? *J Pain Symptom Manage* 2017;54:692–700.
- 11 Ramsenthaler C, Osborne TR, Gao W, *et al.* The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. *BMC Cancer* 2016;16:427.
- 12 Peppercorn JM, Smith TJ, Helft PR, et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011;29:755–60.
- 13 Earle CC, Neville BA, Landrum MB, *et al.* Evaluating claimsbased indicators of the intensity of end-of-life cancer care. *Int J Qual Health Care* 2005;17:505–9.
- 14 McInturf G, Younger K, Sanchez C, et al. Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol 2022;109:559–65.